Refractory vertebral osteomyelitis due to CTX-M-14-producing Escherichia coli at ertapenem treatment in a patient with a coexisting urinary tract infection caused by the same pathogen
Abstract
We report the case of a patient with vertebral osteomyelitis and concurrent urinary tract infection (UTI) in which extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (EC(1)) isolated from urine culture was ciprofloxacin-resistant and ertapenem/imipenem-susceptible. The empirically used oral form of ciprofloxacin was switched to parenteral ertapenem based on the antimicrobial susceptibility. However, vertebral osteomyelitis deteriorated, and despite the disappearance of pyuria and a negative urine culture, ESBL-producing E. coli was isolated from a biopsy of the bony material from the fifth lumbar vertebra (EC(2)) and blood culture (EC(3)) at 10 and 12 days after starting ertapenem, respectively. Ertapenem was switched to imipenem, and defervescence occurred 2 days later; a subsequent blood culture was negative. Genotyping indicated that EC(1), EC(2), and EC(3) were of the same clone, with the ESBL being CTX-M-14. The tested antibiotics had identical minimum inhibitory concentrations against each of these isolates. From the pharmacokinetics/pharmacodynamics points of view, it is reasonable to attribute the ertapenem treatment failure in vertebral osteomyelitis due to ESBL-producing E. coli in this case to the suboptimal ertapenem concentration in the inflammatory bone tissue of the host.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.